European Archives - Page 18 of 1462 - European Medical Journal

Review of the European Association of Urology (EAU) Congress 2026

THE VIBRANT city of London, UK, set the stage for Europe’s leading urological gathering this year: the 41st Annual European Association…

Factors Associated with Inferior Outcomes in Patients with Advanced Urothelial Carcinoma

Enfortumab vedotin plus pembrolizumab (EV+P) is the preferred first-line (1L) regimen for patients with advanced urothelial carcinoma…

Optimising Management of Urinary Incontinence

Optimising Management of Urinary Incontinence

AAT THE European Association of Urology (EAU) Annual Congress 2026, held in London, UK, from 13th–16th March 2026, the session…

The Future of Robotic Surgery

AI IS no longer a distant idea, but an integrated tool significantly impacting medicine and patient care. In this timely session from the…

Results of 20 Years of Follow-Up from ERSPC Rotterdam

Data from a 15-year follow-up of the ProtecT trial, which randomised men to radical prostatectomy (RP), radiotherapy (RT), or active…

Ultrasound Navigation in Robot-Assisted Percutaneous Access

Percutaneous access is essential in procedures such as percutaneous nephrolithotomy, biopsy, and ablation, requiring precise…

Novel Paediatric Low-Dose CT Protocol for Urolithiasis Assessment

Ultrasonography is the recommended first-line investigation for the diagnosis of paediatric urolithiasis.1 Despite higher sensitivity and…

Comparing Automated and Semi-Automated Methods for Measuring Kidney Stone Volumes

With recent emphasis placed on using stone volumes in surgical outcomes research,1-6 there is a need to assess the accuracy and…

9-Valent HPV Vaccine and Genital Wart Recurrence

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide,1 with most sexually active individuals acquiring…

CAR-T Therapy Outcomes Linked to Lymphocyte Growth - EMJ

Lymphocyte Growth Predicts Outcomes After CAR-T Therapy in Lymphoma

Rapid lymphocyte expansion after CAR-T therapy predicts better survival in lymphoma but increases toxicity risk, highlighting its role as a key biomarker.